Furthermore, an elevated proportion of NSCLC patients with CR or PR was also observed in FAT1 mutated subgroup (75.0% vs. 31.9%, Fisher exact test P = 0.022; Fig. 4c). The gene discussed is FAT1; the disease is non-small cell lung carcinoma.